Skip to content

Multicenter clinical study of Uremic Clearance Granule to delay the progression of renal function in diabetic kidney disease

Multicenter clinical study of Uremic Clearance Granule to delay the progression of renal function in diabetic kidney disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001850
Enrollment
Unknown
Registered
2025-09-26
Start date
2025-11-01
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic kidney disease

Interventions

treatment group :Uremic Clearance Granule
control group:Uremic Clearance Granule simulant

Sponsors

Traditional Chinese Medicine Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for DKD disease and syndrome formulated by the project; (2) Aged between 18-75 years old (including 18 and 75 years old); 3)eGFR=60ml/min/1.73m2; (4) The patient or legal representative signs the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Known non-diabetic nephropathy, including clinically relevant renal artery stenosis; (2) Serum potassium > 5.0mmol/L; (3) Glycated hemoglobin > 12%; (4) Complications such as severe infection, severe anemia, electrolyte disorders, or stroke, transient ischemic attack, or acute occurrence in the past 4 weeks Coronary syndrome or hospitalization for worsening heart failure; (5) Patients who have received regular renal replacement therapy or have received dialysis for acute renal failure in the past 12 weeks; (6) Any other condition or treatment that makes the patient unsuitable for this study and does not allow participation in the entire planned study period (e.g., active malignancy). or other diseases that limit life expectancy to <12 months); (7) Pregnancy or lactation or planned pregnancy; (8) Participating in another clinical study of an investigational drug at the same time, using a clinical trial drug.

Design outcomes

Primary

MeasureTime frame
eGFR;

Secondary

MeasureTime frame
Renal composite endpoint events;UACR;TCM syndrome score;

Countries

China

Contacts

Public ContactWenjing Zhao

Traditional Chinese Medicine Hospital Affiliated to Capital Medical University

wenjingz@263.net13621162667

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026